

Luisa M Villar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6734417/publications.pdf>

Version: 2024-02-01

136
papers

4,773
citations

109321

35
h-index

114465

63
g-index

140
all docs

140
docs citations

140
times ranked

5417
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	9.0	455
2	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	3.0	249
3	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. <i>Brain</i> , 2010, 133, 1082-1093.	7.6	240
4	Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. <i>Journal of Clinical Investigation</i> , 2005, 115, 187-194.	8.2	229
5	Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. <i>Annals of Neurology</i> , 2003, 53, 222-226.	5.3	153
6	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015, 138, 918-931.	7.6	147
7	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1802-1809.	3.0	133
8	Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. <i>Neurology</i> , 2002, 59, 555-559.	1.1	119
9	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	7.6	115
10	Clinically isolated syndromes: A new oligoclonal band test accurately predicts conversion to MS. <i>Neurology</i> , 2006, 66, 576-578.	1.1	110
11	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. <i>Brain</i> , 2020, 143, 1414-1430.	7.6	92
12	Intrathecal IgM synthesis in neurologic diseases: Relationship with disability in MS. <i>Neurology</i> , 2002, 58, 824-826.	1.1	85
13	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016, 87, 1076-1084.	1.1	85
14	Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. <i>Brain</i> , 2014, 137, 2703-2714.	7.6	69
15	Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1208-1213.	3.0	68
16	A sensitive and reproducible method for the detection of oligoclonal IgM bands. <i>Journal of Immunological Methods</i> , 2001, 258, 151-155.	1.4	61
17	Early Differential Diagnosis of Multiple Sclerosis Using a New Oligoclonal Band Test. <i>Archives of Neurology</i> , 2005, 62, 574.	4.5	59
18	Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2015, 180, 243-249.	2.6	58

#	ARTICLE	IF	CITATIONS
19	Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. <i>Neuroradiology</i> , 2012, 54, 5-12.	2.2	55
20	High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. <i>Clinica Chimica Acta</i> , 2012, 413, 1813-1816.	1.1	54
21	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. <i>European Journal of Neurology</i> , 2018, 25, 1189-1191.	3.3	53
22	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	3.0	52
23	Immunoglobulin <sc>M</sc> oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2014, 76, 231-240.	5.3	51
24	Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1317-1327.	3.0	49
25	Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma. <i>Clinical and Experimental Immunology</i> , 2008, 82, 390-395.	2.6	48
26	Lipid-specific immunoglobulin <sc>M</sc> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015, 77, 447-457.	5.3	48
27	Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions. <i>Journal of Neuroinflammation</i> , 2019, 16, 220.	7.2	48
28	An ultrasensitive method for the detection of oligoclonal IgG bands. <i>Journal of Immunological Methods</i> , 2004, 284, 141-145.	1.4	47
29	Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis. <i>Archives of Neurology</i> , 2012, 69, 191.	4.5	46
30	Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 1169-1175.	3.3	46
31	Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. <i>Journal of Neuroimmunology</i> , 2012, 247, 86-94.	2.3	45
32	A functional variant that affects exon-skipping and protein expression of <i>SP140</i> as genetic mechanism predisposing to multiple sclerosis. <i>Human Molecular Genetics</i> , 2015, 24, 5619-5627.	2.9	43
33	Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgD ⁺ CD27 ⁺ Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients. <i>Journal of Immunology</i> , 2019, 203, 1650-1664.	0.8	42
34	Immunosenescence in multiple sclerosis: the identification of new therapeutic targets. <i>Autoimmunity Reviews</i> , 2021, 20, 102893.	5.8	41
35	Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus. <i>Scientific Reports</i> , 2017, 7, 44377.	3.3	40
36	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 761-769.	2.9	40

#	ARTICLE	IF	CITATIONS
37	Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	38
38	Soluble Class 1 antigens (sHLA) in CSF and serum of patients with HIV infection. <i>Acta Neurologica Scandinavica</i> , 1990, 82, 14-16.	2.1	36
39	Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1374.	4.8	35
40	Syncytin-1/HERV-W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients. <i>European Journal of Immunology</i> , 2020, 50, 685-694.	2.9	35
41	The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. <i>Journal of Neuroimmunology</i> , 2010, 226, 143-146.	2.3	34
42	CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009, 211, 101-104.	2.3	33
43	Methimazole Has No Dose-Related Effect on the Serum Concentrations of Soluble Class I Major Histocompatibility Complex Antigens, Soluble Interleukin-2 Receptor, and β 2-Microglobulin in Patients with Graves' Disease. <i>Thyroid</i> , 1996, 6, 29-36.	4.5	31
44	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. <i>Human Molecular Genetics</i> , 2016, 25, 308-316.	2.9	31
45	Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. <i>Clinical Immunology</i> , 2010, 137, 51-59.	3.2	30
46	Detection of soluble class I molecules (non hla-a or hla-b) in serum, spleen membranes and lymphocytes in culture. <i>European Journal of Immunology</i> , 1989, 19, 1835-1839.	2.9	29
47	Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 31-43.	3.5	29
48	Factors associated with dimethyl fumarate-induced lymphopenia. <i>Journal of the Neurological Sciences</i> , 2019, 398, 4-8.	0.6	29
49	Validation of semaphorin 7A and ala- β -his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014, 11, 181.	7.2	28
50	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 318-328.	3.8	28
51	Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 266, 34-37.	0.6	27
52	Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 741-752.	3.0	26
53	Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the "hygiene hypothesis"? <i>European Journal of Neurology</i> , 2018, 25, 925-933.	3.3	26
54	High frequency of co-infection by Epstein-Barr virus types 1 and 2 in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1295-1300.	3.0	25

#	ARTICLE	IF	CITATIONS
55	Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. <i>Journal of Immunological Methods</i> , 2011, 371, 170-173.	1.4	25
56	Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2011, 17, 690-694.	3.0	25
57	Identification of the major HHV-6 antigen recognized by cerebrospinal fluid IgG in multiple sclerosis. <i>European Journal of Neurology</i> , 2014, 21, 1096-1101.	3.3	25
58	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018, 15, 265.	7.2	25
59	Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 1194-1196.	1.9	24
60	Increased Soluble Serum HLA Class I Antigens in Patients with Lymphoma. <i>Human Immunology</i> , 1997, 58, 106-111.	2.4	24
61	Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. <i>European Journal of Neurology</i> , 2009, 16, 380-385.	3.3	24
62	Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication. <i>Bone Marrow Transplantation</i> , 2017, 52, 832-838.	2.4	24
63	How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. <i>Gut Microbes</i> , 2020, 12, 1813532.	9.8	24
64	Acetate correlates with disability and immune response in multiple sclerosis. <i>PeerJ</i> , 2020, 8, e10220.	2.0	23
65	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. <i>Journal of Neurology</i> , 2018, 265, 424-430.	3.6	21
66	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 355-363.	3.7	21
67	Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis. <i>Journal of Immunology</i> , 2014, 193, 2147-2156.	0.8	20
68	Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	20
69	Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. <i>Multiple Sclerosis Journal</i> , 2010, 16, 810-815.	3.0	19
70	Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. <i>Clinica Chimica Acta</i> , 2015, 438, 67-69.	1.1	19
71	Intrathecal synthesis of soluble class I antigens in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1992, 36, 77-79.	2.3	17
72	Adaptive Features of Natural Killer Cells in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 2403.	4.8	17

#	ARTICLE	IF	CITATIONS
73	Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. <i>European Journal of Neurology</i> , 2019, 26, 1200-1204.	3.3	17
74	Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 360, 41-44.	0.6	16
75	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 303, 62-65.	2.3	16
76	The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19. <i>Journal of Clinical Immunology</i> , 2021, 41, 315-323.	3.8	16
77	Implication of soluble and membrane HLA class I and serum IL-10 in liver graft acceptance. <i>Human Immunology</i> , 1999, 60, 500-509.	2.4	15
78	CSF Chitinase 3-like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	15
79	IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1652-1661.e1.	2.9	14
80	Clinical usefulness of prognostic biomarkers in optic neuritis. <i>European Journal of Neurology</i> , 2018, 25, 614-618.	3.3	13
81	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 685139.	4.8	13
82	A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1104-1111.	3.0	12
83	Decreased soluble IFN- γ receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. <i>Multiple Sclerosis Journal</i> , 2017, 23, 937-945.	3.0	12
84	Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. <i>Scientific Reports</i> , 2020, 10, 14244.	3.3	12
85	Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. <i>Epigenomics</i> , 2020, 12, 2065-2076.	2.1	12
86	Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. <i>Cells</i> , 2021, 10, 119.	4.1	12
87	Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. <i>Journal of Neurochemistry</i> , 2012, 123, 568-577.	3.9	11
88	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e47.	6.0	11
89	Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. <i>European Journal of Neurology</i> , 2016, 23, 722-728.	3.3	11
90	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. <i>Journal of Neurology</i> , 2018, 265, 24-31.	3.6	11

#	ARTICLE	IF	CITATIONS
91	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1507-1510.	3.0	11
92	DRB1*03:01 Haplotypes: Differential Contribution to Multiple Sclerosis Risk and Specific Association with the Presence of Intrathecal IgM Bands. <i>PLoS ONE</i> , 2012, 7, e31018.	2.5	11
93	Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma. <i>British Journal of Haematology</i> , 2014, 164, 752-755.	2.5	10
94	CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression. <i>British Journal of Haematology</i> , 2002, 119, 70-78.	2.5	9
95	Oligoclonal bandsâ€”a useful tool to avoid MS misdiagnosis. <i>Nature Reviews Neurology</i> , 2013, 9, 303-304.	10.1	9
96	Multimarker risk stratification approach at multiple sclerosis onset. <i>Clinical Immunology</i> , 2017, 181, 43-50.	3.2	9
97	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	2.4	9
98	Whole-Transcriptome Analysis in Peripheral Blood Mononuclear Cells from Patients with Lipid-Specific Oligoclonal IgM Band Characterization Reveals Two Circular RNAs and Two Linear RNAs as Biomarkers of Highly Active Disease. <i>Biomedicines</i> , 2020, 8, 540.	3.2	8
99	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1706-1716.	3.0	8
100	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2018, 15, 296.	7.2	7
101	Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116811.	0.6	7
102	Increased beta 2-microglobulin in CSF of multiple sclerosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1987, 50, 1238-1238.	1.9	6
103	Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013, 261, 98-107.	2.3	6
104	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment. <i>Scientific Reports</i> , 2021, 11, 9299.	3.3	6
105	Soluble class I histocompatibility antigens (s-HLA) and beta 2-microglobulin at delivery. <i>Clinical and Experimental Immunology</i> , 1991, 84, 167-9.	2.6	6
106	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55â€”IL6ST Gene Region in Immature Dendritic Cells. <i>Frontiers in Immunology</i> , 2021, 12, 816930.	4.8	6
107	Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	2.2	5
108	Anti-myelin antibodies play an important role in the susceptibility to develop proteolipid protein-induced experimental autoimmune encephalomyelitis. <i>Clinical and Experimental Immunology</i> , 2014, 175, 202-207.	2.6	5

#	ARTICLE	IF	CITATIONS
109	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. PLoS ONE, 2015, 10, e0134414.	2.5	5
110	A pharmacogenetic study implicates NINJ2 in the response to Interferon- β in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	3.0	5
111	Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 1913.	4.8	5
112	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. Journal of Clinical Medicine, 2020, 9, 625.	2.4	5
113	Short-chain fatty acids during pregnancy in multiple sclerosis: A prospective cohort study. European Journal of Neurology, 2022, 29, 895-900.	3.3	5
114	Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis. Aging Cell, 2021, 20, e13440.	6.7	4
115	Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis. Brain and Behavior, 2021, 11, e2405.	2.2	4
116	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage. Clinical and Translational Medicine, 2022, 12, e837.	4.0	4
117	Soluble Class I Antigen Secretion by Peripheral Blood Lymphocytes in Multiple Sclerosis. European Neurology, 1993, 33, 229-231.	1.4	3
118	Comment on the article by Stauch et al. "Intrathecal IgM synthesis in paediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis". Multiple Sclerosis Journal, 2012, 18, 250-251.	3.0	3
119	Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis. Clinica Chimica Acta, 2019, 488, 135-142.	1.1	3
120	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. Frontiers in Immunology, 2021, 12, 760546.	4.8	3
121	Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington's Disease Patients. PLOS Currents, 2018, 10, .	1.4	3
122	Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression. Frontiers in Immunology, 2021, 12, 798003.	4.8	3
123	Intrathecal synthesis of soluble class I antigens (sHLA) in patients with HIV infection and tuberculous meningitis. Journal of the Neurological Sciences, 1990, 100, 152-154.	0.6	2
124	Importance of age at diagnosis in multiple sclerosis. Expert Review of Neurotherapeutics, 2010, 10, 341-342.	2.8	2
125	Spanish Immunology on the move. European Journal of Immunology, 2015, 45, 1580-1583.	2.9	2
126	Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Revista De Neurologia, 2016, 62, 559-69.	7.8	2

#	ARTICLE	IF	CITATIONS
127	Value of oligoclonal band study in clinically isolated syndromes and multiple sclerosis. Expert Review of Neurotherapeutics, 2008, 8, 1279-1280.	2.8	1
128	Genetic variability affects CNS IgG production in MS. Nature Reviews Neurology, 2015, 11, 313-314.	10.1	1
129	Guía de laboratorio para el diagnóstico y seguimiento de pacientes con gammapatías monoclonales. Revista Clinica Espanola, 2016, 216, 128-134.	0.6	1
130	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Human Mutation, 2020, 41, 1308-1320.	2.5	1
131	Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. Frontiers in Medicine, 2021, 8, 683990.	2.6	1
132	Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients. Bone Marrow Transplantation, 2017, 52, 1206-1207.	2.4	1
133	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	4.8	1
134	Current concepts in immunology. Expert Review of Clinical Immunology, 2008, 4, 559-564.	3.0	0
135	Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine. British Journal of Dermatology, 2018, 179, 765-766.	1.5	0
136	gMS-Classifier1 does not predict disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1010-1011.	3.0	0